**Nanoparticle or conventional adjuvants: which one improves immune response against Brucellosis?**

Soheil Yousefi 1, Tooba Abbassi-Daloii 1, Mojtaba Tahmoorespur 1, Mohammad Hadi Sekhavati 1*

1Department of Animal Science, Ferdowsi University of Mashhad, Mashhad, Iran

**ABSTRACT**

**Objective(s):** Brucellosis is a common infectious disease among animals and humans. While subunit vaccines could be used as an efficient strategy against pathogens, they usually seem to be less immunogenic than live or killed vaccines. However, the use of a suitable adjuvant accompanied by subunit vaccines can be a good alternative to enhance the immune response.

**Materials and Methods:** To find a proper adjuvant against Brucellosis, the immune response of induced mice by Aluminum Hydroxide (AH), Incomplete Freund (IFA), and Chitosan Nanoparticle (CS) adjuvants in individuals and in combination with CS were assessed.

**Results:** Immunization with CS stimulated higher interferon gamma (IFN-γ) immunity, while there were no significant differences between rOMP25 (IFA), rOMP25 (AH), rOMP25 (AH-CS) and rOMP25 (IFA-CS) recombinant proteins. Tumor necrosis factor alpha (TNF-α) analysis revealed there were no significant differences between immunized groups and the positive control group, except for the treatment formulated in single IFA. Furthermore, unlike IFN-γ, there was a reverse interleukin-4 (IL-4) immune response trend for treatments, as rOMP25 (CS) displayed the lowest response. rOMP25 (CS) induced higher titer of total antibody than the other ones. Although the recombinant proteins emulsified in different adjuvants induced similar titer of IgG1 antibody, the ones that were formulated in CS, IFA and IFA-CS showed a higher titer of IgG2a. The cell proliferation assay demonstrating the antigen-specific cell proliferative response could be promoted after immunization with CS.

**Conclusion:** CS whether single or in combination with IF adjuvants has potential to improve Th1-Th2 responses.

---

**Introduction**

Infectious diseases after cardiovascular ones are the second cause of worldwide deaths (1, 2). Brucellosis, as one of the seven global neglected zoonotic diseases caused by a genus of Gram-negative Brucella bacterium, is a common infectious disease between animals and humans (2, 3). Vaccination is one of the most effective public health interventions ever performed and has vast impact on preventing infectious diseases (4, 5). Brucellosis causes many economic and health issues that are not preventable using inoculation (6). Therefore, designing an efficient vaccine candidate that can stimulate a protective immune response against this infection seems to be critical (4). Consequently, the development of efficient vaccines will be through using well matched antigens and adjuvants (5). In the 1920s, the concept of adjuvant, which means to aid, was primarily used by Ramon (3). Adjuvants are substances added to vaccines to increase antigen immunogenicity by contributing to the initiation of the innate immune response (4). The adjuvant enhances the efficacy of the vaccine through increasing the immunogenicity of recombinant proteins, decreasing the amount of antigens needed to form protective immunity, raising functional antibody titer, generating faster and long-lasting immune responses, inducing robust cell-mediated immunity, providing broad protection (cross-reactivity), and as an antigen delivery system improves the antigen uptake (1, 7-9). Adjuvants can be classified based on their physicochemical features, sources, and mechanisms of action (10). Aluminum Hydroxide (AH) and Freund Adjuvants (FA) are two kinds of mineral salt adjuvants and Chitosan (CS) is a sort of mucosal adjuvant that are used in the current study. Glenny et al. (11) demonstrated the adjuvant activity of aluminum compounds that were based on absorbed diphtheria toxoid. After around a decade, aluminum-based compounds remained the main used adjuvants (12). The AH mechanism includes the formation of a depot at the vaccination site, enhancing antigen availability and activation of antigen presenting cells (13). However, it is a poor inducer of cell-mediated immune response, which is essential for protection against many pathogens such as Brucellosis and it is important to increase allergenicity and neurotoxicity as well (14-18). So after Alum, Complete Freund’s Adjuvant (CFA), which consists of heat-killed Mycobacterium tuberculosis was developed (19, 20). CFA is a feasible adjuvant, although it is too toxic and causes severe local reactions in humans. Therefore, Incomplete Freund (IFA), which lacks killed Mycobacterium found in CFA, was introduced (20, 21). It stimulates predominantly Th2 response through the formation of a depot at the injection site, enabling the gradual antigen release and stimulating antibody to produce plasma cells (22). IFA is routinely used for boosting immunizations subsequent to CFA (23). CS is
produced using the deacetylation of chitin, the major element of the shells of crustaceans (24, 25). CS as a nontoxic immunological adjuvant can induce both humoral and cell-mediated immunity by stimulating macrophages, natural killer cells, dendritic cells, and B and T lymphocytes (26-33). Also, it can be used as a vaccine delivery carrier (34).

Herein we assumed that CS can have a better potential to promote an immune response against Brucella by stimulating the innate immune system. In this regard, the immune responses of three different adjuvants were assessed when they were injected either individually or in combination with CS. OMP25 was used as a model antigen because it is the major antigen involved in the survival of Brucella and it is also highly conserved among different Brucella species (35).

Materials and Methods

Bacterial strains and recombinant protein productions

B. melitensis strain Rev 1 was obtained from the Brucella culture collection of Razi Vaccine and Serum Research Institute ( Mashhad, Iran), and cultured as described (36). The OMP25 recombinant protein was produced as previously described (35).

Experimental groups and immunization

Six-week-old female BALB/c mice (obtained from Razi Vaccine and Serum Research Institute, Iran and kept according to institutional policies for animal health and welfare) were randomly classified into nine experimental groups containing rOMP25, rOMP25 (CS), rOMP25 (IFA), rOMP25 (AH), rOMP25 (AH-CS), rOMP25 (IFA-CS), B. melitensis Rev 1, PBS - pET-32a (+) and PBS (5 mice per group). As immunization was performed intraperitoneally (IP) with OMP25 recombinant protein (20 µg per injection) emulsified in three different adjuvants including individual injections of AH, IFA and CS with concentration of 0.5 mg/ml for each one (Sigma, USA) or combination of AH and IFA with CS. Additionally, mice were administered rOMP25 without adjuvant, which was used to determine baseline immune responses elicited by antigen alone and to correct the probable impact of this antigen on immune responses to get unbiased results. Therefore, different levels of stimulated immune responses are expected due to different adjuvants. Moreover, there were two different negative control groups including phosphate buffered saline (PBS) and PBS containing self-expressed pET-32a (+) vector. A dose of live attenuated vaccine B. melitensis Rev1 (10^6 CFU/mice) was injected as positive control group. PBS was added to each vaccine mixture to a final volume of 300 µl per injection. All experimental groups were immunized three times (days 0, 15, and 30).

Antibody and isotype responses

Mice were bled for serum collection two weeks after the last injection. Serum was separated from blood by centrifugation at 3000 g for 20 min and the supernatant was used to determine humoral response using an indirect enzyme-linked immunosorbent assay (ELISA). The purified rOMP25 (1 µg/ml) protein was coated in 96-well plates (Nunc, Naperville, IL) and incubated for 24 hr at 37 °C. Wells were washed three times with PBS containing 0.05% Tween 20 (TPBS) and blocked for 1 hr at 37 °C with 5% skimmed milk in PBS. Plates were afterward incubated with serial dilutions of mouse sera (1/100 to 1/10000) for 2 hr at room temperature and washed three times as above. Then wells were incubated with 100 µl of 1/10000 dilution of anti-mouse IgG–Horseradish Peroxidase (HRP) conjugate antibody (Sigma, USA) for 2 hr at 37 °C. Plates were washed five times and incubated for 15 min with 100 µl of 3, 3’, 5’, tetramethyl-benzidine (TMB) substrate in the dark and the reaction was stopped using 2N H₂SO₄. Finally, color intensity was measured at OD₄₅₀ nm with an ELISA plate reader. To determine the Th1/Th2 immune response bias, IgG isotyping was performed under the same condition using 100 µl of 1/4000 dilution of goat anti-mouse IgG1-HRP and IgG2a-HRP conjugated antibodies (Sigma, USA). The results for IgG and IgG isotypes were represented as the mean of triplicates ± SE of the OD₄₅₀ nm from five samples.

Cytokines determination

To evaluate the cellular immune response induced by different immunization strategies, mice were sacrificed two weeks after the final injection and their spleens were homogenized in 10 ml PBS containing 5 mM ethylenediamine-tetraacetic acid (PBS-EDTA) on ice. The cells were washed twice with PBS-EDTA and mononuclear cells were isolated. They were then cultured in RPMI 1640 (supplemented with 4 mM l-glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin, and 10% heat-inactivated FBS) at 37 °C in 5% CO₂ (37). Splenocytes were then counted and a total number of 4×10⁶ cells were seeded in a 24-well plate and stimulated in vitro with 10 µg/ml of recombinant protein emulsified in different adjuvants for 48 hr at 37 °C in 5% CO₂. In order to measure the different cytokine levels, cell culture supernatants were collected and centrifuged at 300 g for 10 min and stored at -80 °C. Interferon-gamma (IFN-γ), tumor necrosis factor alpha (TNF-α), and interleukin-4 (IL-4) levels were measured by sandwich ELISA according to the manufacturer’s instructions (Mabtech, Nacka, Sweden).

Lymphocyte proliferation assay

As described previously in the cytokines determination section, spleens were dissected from the mice and suspended in cold sterile PBS containing 2% FBS. RBCs were lysed using lysis buffer. The single-cell suspension was adjusted to 3×10⁶ cells/ml and afterward supplemented in RPMI 1640. Then the cell suspension was dispensed into a 96-well plate in triplicate and incubated with 10 µg/ml of the recombinant protein as antigen recall for 48 hr. Before the incubation ended, 20 µl MTT (3-(4,5 dimethylthiazole-2-yl)-2,5 diphenyl tetrazolium bromide, 5 mg/ml) was added. After 4 hr, 100 µl of dimethyl sulfoxide (DMSO) was added followed by 1 hr incubation. Absorbance was measured using a spectrophotometric plate reader at 590 nm. The stimulation index (SI) was calculated according to the following equation: average OD of stimulated wells/average OD of un-stimulated wells.
Statistical analysis

Data were analyzed using one-way analysis of variance (ANOVA), followed by Tukey’s post hoc test analysis for multiple comparisons using GraphPad Prism v6.07 software (GraphPad Software Inc., San Diego, CA, USA). Values were presented as mean±SE in both text and figures. *P*-values less than 0.05 were considered statistically significant.

Results

Chitosan nanoparticle adjuvant increased humoral immune response

To evaluate the humoral immune response elicited by different immunization strategies, immunoglobulin G (IgG) antibodies were measured using specific indirect ELISA. The result of total antibody response showed immunization with different adjuvants raised higher levels of antibody titer compared to the negative control groups (Figure 1A). Mice immunized with rOMP25 (CS) showed higher total antibody titer than other groups, while it was still lower than the positive control group (Figure 1A). Furthermore, other treatments that were formulated in different adjuvants stimulated a roughly similar total antibody level (Figure 1A). Moreover, IgG1 and IgG2a were evaluated as Th2 and Th1 response markers, respectively. The results illustrated that all treatments elicited higher levels of IgG1 as well as IgG2a antibodies compared with negative control groups (*P*<0.05, Figure 1B). There were no statistically significant differences in IgG1 titer between treatments that were formulated in different adjuvants (rOMP25 (CS), rOMP25 (IFA-CS), rOMP25 (IFA), rOMP25 (AH) and rOMP25 (AH-CS)); additionally, the positive control group showed no statistically significant difference with other treatments that were emulsified in different adjuvants (except rOMP25 (AH-CS)) (*P*<0.05, Figure 1B).

The titers of IgG2a antibody in all treatments that were formulated in adjuvants were also higher and lower than negative and positive control groups, respectively: rOMP25 (AH) and rOMP25 (CS) vaccines formed the lowest and the highest amounts of IgG2a antibody titer, respectively among emulsified treatments in adjuvants (*P*<0.05, Figure 1B). Moreover, the antibody titer demonstrated skew from IgG1 to IgG2a in immunized...
mice indicating strong bent of Th1 immune response, however, there were no significant differences between groups immunized with adjuvants, but they showed statistically higher IgG2a/IgG1 ratio than baseline and negative control groups as well (Figure 1C). Also, rOMP25 (CS) showed the biggest shift from IgG1 to IgG2a among immunized groups with different adjuvants (rOMP25 (IFA-CS), rOMP25 (IFA), rOMP25 (AH), and rOMP25 (AH-CS)), and the average IgG2a/IgG1 ratio was estimated ~ 1.2 (Figure 1C).

**Immunization with chitosan nanoparticle adjuvant efficiently induced cytokine responses**

Results revealed that all immunizations induced higher titers of both Th1 and Th2 cytokines than negative control groups (Figure 2). The vaccine that was only emulsified in the CS adjuvant (rOMP25 (CS)) induced significantly higher titer of INF-γ cytokine response than other immunized groups, although it was still lower than the positive control group ($P<0.05$, Figure 2A). There were no further statistically significant differences between rOMP25 (IFA), rOMP25 (AH), rOMP25 (IFA-CS), and rOMP25 (AH-CS) treatments; rOMP25 (IFA) and rOMP25 (AH-CS) showed no statistical difference with the group treated without adjuvant (rOMP25) ($P<0.05$, Figure 2A). TNF-α analysis exhibited no significant differences between immunized treatment using emulsification in adjuvants and the positive control group, although rOMP25 (IFA) showed statistically no difference compared to rOMP25 (Figure 2B). rOMP25 (CS) showed the lowest IL-4 titer among formulated treatments, whilst there were no significant differences between other immunized groups for IL-4 cytokine (Figure 2C). Also, the positive control group induced the highest titer of IL-4 among all immunization schemes (Figure 2C). Generally, treatments formulated in different adjuvants induced higher titers of both Th1 and Th2 cytokine responses compared with negative control groups, as rOMP25 (CS) and rOMP25 (AH), slightly, showed better efficiency than other treatments.

**Lymphocyte proliferation**

Lymphocyte proliferation index is increased if the absorbance values of the experimental samples are higher than that of the negative control group and vice versa. In this regard, lymphocyte proliferation index was measured after stimulating splenocytes of immunized mice in vitro. There was no difference between the positive control group and rOMP25 (CS), whilst the former of which had a significant difference with other groups ($P<0.05$, Figure 3). Finally, treatments containing CS showed better performance than other groups with different adjuvants, whilst it was not significant.

**Discussion**

Vaccination is considered the most efficient and cost-effective tool to prevent a variety of infectious pathogens, whilst inducing a strong immune response to provide long-term protection still remains the main issue. To overcome this problem, using an appropriate adjuvant with vaccines would be helpful (1, 2). Several studies showed alum, IFA and CS could activate the innate
immune response, whilst in some cases, consumption of both alum and IFA showed strong side effects in humans and animals, likewise, Alum could not efficiently induce an immune response when it was used alone (38-44). Therefore, for the first time in the current study to find the best adjuvant combination against Brucellosis, the impact of different adjuvants on improving the humoral and cellular immune responses was evaluated. Furthermore, since other adjuvants such as alum did not have proper efficiency in oral immunization (38, 39), the IP route was performed to consider all groups under the same conditions.

The comparison results of AH, IFA, and CS showed immunization with CS (rOMP25 (CS)) not only induced better humoral and cellular immunity but also in some cases there were no statistically significant differences between rOMP25 (CS) and positive control groups (Figures 1 and 2). rOMP25 (AH) stimulated cellular immunity more than humoral immunity, while rOMP25 (IFA) showed the opposite performance compared with rOMP25 (AH). Moreover, the rOMP25 (IFA-CS) group showed slightly higher cellular responses (but not significant) than individual injection of IFA, although there was a reverse immunity response level for rOMP25 (AH-CS) treatment compared with the group with rOMP25 (AH) injection. rOMP25 (IFA-CS) and rOMP25 (AH-CS) injections showed no enhancement to humoral responses compared with individual inclusion of IP and AH (Figure 2). The cell proliferative response indicated vaccination with OMP25 elicits a vigorous antigen-specific cell proliferative response that could be promoted after the immunization with CS and this would be vital for controlling Brucellosis. Overall, in the current study immunization with rOMP25(CS) showed better performance in inducing IFN-γ, TNF-α, IgG2a, and lymphocyte proliferation index and reduced IL-4, indicating the tendency of this adjuvant to stimulate Th1 immune response. The specifically related to CS results of the current study can be explained through functional aspects of IFN-γ and TNF-α, which are two important components of Th1 immune response contributing to controlling Brucellosis by stimulating phagocytic activity of macrophages and apoptosis in infected macrophages (45, 46). The development of both CD4+ ( secreting IFN-γ upregulating the anti-Brucella activity of macrophages) and CD8+ (secretion IFN-γ and lysing Brucella-infected cells) T cells are two main protective responses in the host (47). Moreover, IFN-γ plays a key role in the switching of IgG to IgG2a, which is important in protecting against infection (47). Also, secretion of IFN-γ from CD4+ cells is down-regulated by IL-4 causing exacerbation of the Brucella infection (48, 49).

Our results were in agreement with a study (42) that found antigens emulsified in IFA induced higher antibody titers than injection of antigens without adjuvants in a human influenza vaccine. Additionally, our results are consistent with another study (50) that reported CS noticeably enhanced both cellular and humoral immune responses and stimulated a balanced Th1/Th2 response. That study suggested CS would be a safe and efficient adjuvant candidate for a wide spectrum of prophylactic and therapeutic vaccines. Recently, researchers (51, 52) used CS as an adjuvant in their studies and found a remarkable improvement in immune responses against Brucellosis. Some (53, 54) studied the effect of IFA and N’-Trimethyl chitosan (TMC) on Omp19 immunogenicity against Brucella abortus and Brucella melitensis. They found Omp19-IFA and TMC/ Omp19 could induce Th1 and Th2 immune responses, respectively, while TMC/Omp19 immunization induced a mixed Th1/Th2 immune response. In addition, a study (55) found that N’-Trimethyl chitosan nanoparticles loaded with influenza subunit antigen-stimulated higher titer of IgG and it could be a feasible new delivery system for influenza antigens. There exist further studies showing the potential of the CS adjuvant, which are also in agreement with the results of the present study. Carroll et al. (44) indicated CS elicits dendritic cells and Th1 responses to promote cellular immunity by engaging the DNA sensor cGAS-STING pathway. They also revealed that CS would be a suitable alternative for alum, although the adjuvanticity mechanism is still underlying (56). Moreover, in contrast with Alum, CS lacks inhibition impact on interleukin-12 production. Additionally, antigen-specific Th1, as well as Th17 responses, were promoted by CS and they have key roles in enhancing immunoglobulin G2c antibody responses (57-59).

Conclusion
In as much as there is no efficient subunit vaccine with a suitable immune response against Brucellosis, CS as an adjuvant individually can improve stimulation of Th1 response, which is essential to deal with infectious diseases. However, the protection efficiency of CS should be examined in further experiments involving domestic animals.

Acknowledgment
The present study was funded by Iran National Science Foundation (infsgov.ir, grant no. 92041813). The authors would like to express their gratitude to INFS and Ferdowsi University of Mashhad, Iran, for their support.

Conflict of Interest
All authors declared no conflict of interest in present manuscript.

References
1. Lee S, Nguyen MT. Recent advances of vaccine adjuvants for infectious diseases. Immune Netw 2015;15:51-57.
2. Petrovsky N, Aguilar JC. Vaccine adjuvants: current state and future trends. Immunol Cell Biol 2004;82:488-496.
3. Ramon G. Sur l’augmentation anormale de l’antitoxine chez les chevaux producteurs de serum antidiphterique. Bull Soc Centr Med Vet 1925;101:227-234.
4. Apostólisco JdS, Lunardelli VAS, Coirada FC, Boscardin SB, Rosa DS. Adjuvants: classification, modus operandi, and licensing. J Immunol Res 2016;1459394.
5. Pasquale AD, Preiss S, Silva FTD, Garçon N. Vaccine adjuvants: current state and future trends. J Immunol Res 2016;1459394.
6. Carvalho TF, Haddad JP, Paixão TA, Santos RL. Meta-Analysis and advancement of brucellosis vaccinology. PLoS One 2016;11:e0166582.
7. Douce G, Turcotte C, Cropley I, Roberts M, Pizzi M, Domenghini M, et al. Mutants of Escherichia coli heat-labile toxin lacking ADP-ribose/transferase activity act as nontoxic.
mucosal adjuvants. Proc Natl Acad Sci 1995;92:1644-1648.
8. Marx PA, Companys RW, Gettie A, Staas JK, Gilley RM, Mulligan MJ, et al. Protection against vaginal SIV transmission with microencapsulated vaccine. Science 1993;260:1323-1327.
9. McElrath MJ. Selection of potent immunological adjuvants for vaccine construction. Semin Cancer Biol 1995;3:375-385.
10. Singh O, O'hagan DT. Recent advances in vaccine adjuvants. Pharm Res 2002;19:715-728.
11. Glenny A, Pope C, Waddington H, Wallace U. The antigenic value of toxoid precipitated by potassium alum. J Pathol Bacteriol 1926;29:31-40.
12. Vogel FR, Powell MF. A compendium of vaccine adjuvants and excipients. Pharm Biotechnol 1995; 141-228.
13. Morefield GL, Sokolovska A, Jiang D, Hogen-Esch H, Robinson JP, Hem SL. Role of aluminum-containing adjuvants in antigen internalization by dendritic cells in vitro. Vaccine 2005;23:1588-95.
14. Brewer JM, Conacher M, Satsoskar A, Bluetthmann H, Alexander J. In interleukin-4 deficient mice, alum not only generates T helper 1 responses equivalent to Freund’s complete adjuvant, but continues to induce T helper 2 cytokine production. Eur J Immunol 1996;26:2062-2066.
15. Schirmerick R, Melber K, Martens T, Reimann J. Antibody and cytokine T-cell responses to soluble hepatitis B virus (HBV) S antigen in mice: implication for the pathogenesis of HBV-induced hepatitis. J Viral 1994;68:1418-1426.
16. Traquina P, Morandi M, Contorni M, Van Nest G. MF59 adjuvant enhances the antibody response to recombinant hepatitis B surface antigen vaccine in primates. J Infect Dis 1996;174:1168-1175.
17. Audibert FM, Lise LD. Adjuvants: current status, clinical perspectives and future prospects. Trends Pharmacol sci 1993;14:174-8.
18. Goto N, Kato H, Maeyama J, Eto K, Yoshihara S. Studies on the toxicities of aluminium hydroxide and calcium phosphate as immunological adjuvants for vaccines. Vaccine 1993;11:914-918.
19. Freund J, Casals J, Hosmer EP. Sensitization and antibody formation after injection of tubercle bacilli and paraffin oil. Exp Biol Med 1937;37:509-513.
20. Stuart-Harris C. Adjuvant influenza vaccines. Bull World Health Organ 1969;41:615-621.
21. Lindblad EB. Aluminium compounds for use in vaccines. Immunol Cell Biol 2004;82:497-505.
22. Freund J. The mode of action of immunologic adjuvants. Bibl Tuberc 1956;10:130-148.
23. Moreira LO, Smith AM, DeFreitas AA, Qualls JE, El Kasmi B. Immunological activity of chitin and its derivatives. Vaccine 1994;12:93-99.
24. Knorr D. Use of chitinous polymers in food: a challenge and excipients. Pharm Biotechnol 1995; 141-228.
25. Kurita K. Chemistry and application of chitin and chitosan. Bull World Health Organ 1969;41:615-621.
26. Zhu B, Qie Y, Wang J, Zhang Y, Wang Q, et al. Chitosan microspheres enhance the immunogenicity of an Ag85B-based fusion protein containing multiple T-cell epitopes of Mycobacterium tuberculosis. Eur J Pharm Biopharm 2007;66:318-326.
27. Nishimura K, Nishimura S, Nishi N, Seki S, Tokura S, Azuma M. Immunological activity of chitin and its derivatives. Vaccine 1994;12:93-99.
28. Peluso G, Petillo O, Ranieri M, Santini M, Ambrosic L, Calabrò D, et al. Chitosan-mediated stimulation of macrophage function. Biomaterials 1994;15:1215-1220.
29. Seferian GP, Martinez ML. Immune stimulating activity of two new chitosan containing adjuvant formulations. Vaccine 2000;19:661-668.
30. Shibata Y, Foster LA, Metzger WJ, Myrvik QN. Alveolar macrophage priming by intravenous administration of chitin particles, polymers of N-acetyl-D-glucosamine, in mice. Infect Immun 1997;65:1734-1741.
31. Suzuki K, Okawa Y, Hashimoto K, Suzuki S, Suzuki M. Protecting effect of chitin and chitosan on experimentally induced murine candidiasis. Microbiol Immunol 1984;28:903-912.
32. Van der Lubben I, Verhoef J, Borchard G, Junginger H. Chitosan for mucosal vaccination. Adv Drug Deliv Rev 2001;52:139-144.
33. Villiers C, Chevallet M, Diemer H, Courdier R, Freitas H, Van Dorsselaer A, et al. From secretome analysis to immunology chitosan induces major alterations in the activation of dendritic cells via a TLR4-dependent mechanism. Mol Cell Proteomics 2009;8:1252-1264.
34. De Campos AM, Sanchez A, Alonso Maj. Chitosan nanoparticles: a new vehicle for the improvement of the delivery of drugs to the ocular surface. Application to cyclosporin A.Int J Pharm 2001;224:159-168.
35. Yousefi S, Tahmoorespur M, Sekhavati MH. Cloning, expression and molecular analysis of Iranian Brucella melitensis Omp25 gene for designing a subunit vaccine. Res Pharm Sci 2016;11:412-416.
36. Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning: A Laboratory Manual: Cold Spring Harbor Laboratory Press; 1989.
37. Ghasemi A, Jedd-Tehrani M, Mautner J, Salari MH, Zarnani A-H. Simultaneous immunization of mice with Omp31 and TF provides protection against Brucella melitensis infection. Vaccine 2015;33:5532-5538.
38. Lambrecht BN, Kool M, Willart MA, Hammad H. Mechanism of action of clinically approved adjuvants. Curr Opin Immunol 2009;21:23-29.
39. Marrack P, McKee AS, Munks MW. Towards an understanding of the adjuvant action of aluminium. Nat Rev Immunol 2009;9:287-293.
40. GIES WJ. Some objections to the use of aluminum bivalent-powder. JAMA 1911;5:816-821.
41. Tomlin inov L, A Shaw C. Aluminum vaccine adjuvants: are they safe? Curr Med Chem 2011;18:2630-2637.
42. Salk JE, Laurent AM. The use of adjuvants in studies on influenza immunization: I. Measurements in monkeys of the dimensions of antigenicity of virus-mineral oil emulsions. J Exp Med 1952;95:429-447.
43. Savelkoul HF, Ferro VA, Strioga MM, Schijns VE. Choice and design of adjuvants for parenteral and mucosal vaccines. Vaccines 2015;3:148-171.
44. Carroll EC, Jin L, Miliardi L, Morin I, Munson-Wolf N, Oleszczuka E, Moran HB, et al. The vaccine adjuvant chitosan promotes cellular immunity via DNA sensor cGAS-STING-dependent induction of type I interferons. Immunity 2016;44:597-608.
45. Pasquali P, Adone R, Gasbarre LC, Pistoia C, Ciuchini F. Mouse cytokine profiles associated with Brucella abortus RB51 vaccination or B. abortus 2308 infection. Infect Immun 2001;69:6541-6544.
46. Jiang X, Baldwin CL. Effects of cytokines on intracellular growth of Brucella abortus. Infect Immun 1993;61:124-134.
47. Araya LN, Elzer PH, Rowe GE, Enright FM, Winter AJ. Temporal development of protective cell-mediated and humoral immunity in BALB/c mice infected with Brucella abortus. J Immunol 1989;143:330-3337.
48. Zhan Y, Kelso A, Cheers C. Differential activation of Brucella-reactive CD4+ T cells by Brucella infection or immunization and design of adjuvants for parenteral and mucosal vaccines. Nat Immunol 2009;21:23-29.
49. Marrack P, McKee AS, Munks MW. Towards an understanding of the adjuvant action of aluminium. Nat Rev Immunol 2009;9:287-293.
50. GIES WJ. Some objections to the use of aluminum bivalent-powder. JAMA 1911;5:816-821.
51. Abbassi-Daloii T, Yousefi S, Seikhavati MH, Tahmoorespur M. Impact of heat shock protein 60KD in combination with outer membrane proteins on immune response against Brucella melitensis. APMIS 2018;126:65-75.
52. Yousefi S, Abbassi-Daloii T, Seikhavati MH, Tahmoorespur M. Evaluation of immune responses induced by polymeric OMP25-BLS Brucella antigen. Microb Pathog 2018;115:50-56.
53. Abkar M, Lotfi AS, Amani J, Eskandari K, Ramandi ME, Salimian J, et al. Survey of Omp19 immunogenicity against Brucella abortus and Brucella melitensis: influence of nanoparticulation versus traditional immunization. Vet Res Commu 2015;39:217-228.
54. Abkar M, Fasihi-Ramandi M, Kooshki H, Sahebghadam Lotfi A. Oral immunization of mice with Omp31-loaded N-trimethyl chitosan nanoparticles induces high protection against Brucella melitensis infection. Int J Nanomedicine 2017;12:8769-8778.
55. Amidi M, Romeijn SG, Verhoef JC, Junginger HE, Bungener L, Huckriede A, et al. N-Trimethyl chitosan (TMC) nanoparticles loaded with influenza subunit antigen for intranasal vaccination: Biological properties and immunogenicity in a mouse model. Vaccine 2007;25:144-53.
56. Vasiliev YM. Chitosan-based vaccine adjuvants: incomplete characterization complicates preclinical and clinical evaluation. Expert Rev Vaccines 2015;14:37-53.
57. Coffman RL, Sher A, Seder RA. Vaccine adjuvants: putting innate immunity to work. Immunity 2010;33:492-503.
58. Mori A, Oleszycka E, Sharp FA, Coleman M, Ozasa Y, Singh M, et al. The vaccine adjuvant alum inhibits IL-12 by promoting PI3 kinase signaling while chitosan does not inhibit IL-12 and enhances Th1 and Th17 responses. Eur J Immunol 2012;42:2709-2719.
59. Riteau N, Sher A. Chitosan: an adjuvant with an unanticipated STING. Immunity 2016;44:522-524.